APAC CIO Outlook
  • Home
  • CXO Insights
  • CIO Views
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • About us
Apac
  • Admired Tech

    Agile

    AI Healthcare

    Artificial Intelligence

    Augmented Reality

    Aviation

    Big Data

    Blockchain

    Cloud

    Cryptocurrency

    Cyber Security

    Digital Transformation

    Drone

    HPC

    Infrared

    Internet of Things

    Networking

    PropTech

    Remote Work

    Scheduling Software

    Simulation

    Startup

    Storage

    Wireless

  • Banking

    E-Commerce

    Education

    FinTech

    Food and Beverages

    Healthcare

    Insurance

    Legal

    Manufacturing

    Pharma and Life Science

    Retail

    Travel and Hospitality

  • Atlassian

    CISCO

    Microsoft

    Oracle

    Salesforce

    SAP

    ServiceNow

  • Business Intelligence

    CEM

    Cloud-based Planning

    Cognitive

    Compliance

    Contact Center

    Contact Tracing

    Contactless Payments

    Content Management System

    Corporate Finance

    CRM

    Custom Software Development

    Data Center

    Enterprise Architecture

    Enterprise Communications

    Enterprise Contract Management

    ERP

    Field Service

    HR Technology

    IT Service Management

    Managed Services

    Procurement

    Product Management

    RegTech

    Revenue Management

    Sales Tech

Menu
    • Augmented Reality
    • Agile
    • Cognitive
    • Cyber Security
    • Digital Transformation
    • Atlassian
    • E-Commerce
    • Managed Services
    • RegTech
    • CISCO
    • Blockchain
    • IoT
    • MORE
    #

    Apac CIO Outlook Weekly Brief

    ×

    Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Apac CIO Outlook

    Subscribe

    loading

    THANK YOU FOR SUBSCRIBING

    • Home
    • News
    • Biotech
    Editor's Pick (1 - 4 of 8)
    left
    Framework of Three Horizons to Manage Current and Future Growth

    Clark Golestani, VP & CIO, Merck

    The Changing Role of CIO in the Biopharmaceutical Industry

    Andy Newsom, CIO, CSL Behring

    Formula Five For Biotech IT

    Jeffrey Keisling, CIO and SVP, Pfizer

    Finding Answers in R&D Data is a Team Sport

    Dan Hausman,

    Plant Biotechnology Success Requires Collaboration, Proactive Strategy

    Tim Hassinger, President and CEO, Dow AgroSciences

    The Biotech IT PMO 2.0

    Paul Ritchie,

    The Biotech CIO Roadmap in a Sea of Change

    Amit Shah, VP of IT- Enterprise Applications & Systems, Excelitas Technologies

    The Internet of Things in Healthcare:Smart Strategies to Deliver Better Value

    Miguel Louzan, VP-IT, UCB, Inc.

    right

    Preventing Opioid Use Disorder with reSET-OTM

    By Apac CIO Outlook | Monday, April 15, 2019
    Tweet

    Sandoz is an international leader in generic and biosimilar medicines.  The firm, an integral part of the Novartis Group, discovers new ways to enable people to extend their lives. With ground-breaking, new approaches to help people around the world access high-quality medicine, Sandoz contributes to effectively addressing healthcare needs. In 2017, the company’s sales amounted to around $10.1 billion, covering the portfolio of roughly 1,000 molecules in all major therapeutic areas, and their products reached more than 500 million patients in 2017.

    When it comes to digital prescription therapies, Pear Therapeutics is a leading company. In order to improve patient outcomes and better engagement, and tracking tools for clinicians, the company redefines medicine by providing clinically validated software-based therapeutics. Pear has a product pipeline across therapeutic areas including severe mental and neurological conditions. Pear has a product pipeline. The lead product of Pear, reSET, treated the drug use disorders and received FDA marketing authorization in the field of disease for the first digital prescribed therapy. The FDA approved marketing clearance in December 2018 for Pear's second product, reSET-O(TM), for treatment of the Opioid Use Disorder.

    The U.S. commercial release of reSET-O(TM) for patients with Opioid Use Disruption (OUD) has recently been announced by Sandoz Inc,  Novartis division and Pear Therapeutic, Inc. ReSET-O is available immediately, cleared in December by the Food and Drug Administration of the U.S. (FDA).

    The reSET-O Digital Therapeutic Prescription (PDT) is an outpatient 12 weeks of cognitive behavioral therapy. It includes Transmucosal buprenorphine, a common drug used to treat opioid addiction and contingency management to encourage positive behavior. Only patients 18 years old or older under clinic care are available with a prescription for reSET-O.

    The efficacy of the reSET-O was measured with or without the addition of the reSET-O equivalent therapeutic education system (TES), in a crucial randomized test of 170 patients seeking OUD therapy, supervision of the treatment with supervised buprenorphine paired with a program of conduct therapy. The clinical trial showed that the total retention rate of reSET-O therapy for patients not taking reSET-O was 82.4 percent for 12 weeks of the treatment, compared to 68.4 percent in total.

    reSET-O also provides healthcare providers with the clinician dashboard as a training, monitoring, and reminder tool. The dashboard allows clinicians to gain a broader view of the recovery progress of their patients, including reported adhesion to patients’ buprenorphine so that more transparency can be achieved during in-person therapy.
    See also: 
    Prnewswire | CIO Review
    Youtube | CIO Review

    Weekly Brief

    loading
    Top 10 Compliance Solution Companies - 2021

    Featured Vendors

    MasterSAM

    Sanjeev Dhar, MD

    entity solutions

    Matthew Franceschini, CEO & Co-founder

    ON THE DECK

    Compliance 2021

    Top Vendors

    Compliance 2020

    Top Vendors

    Previous Next

    I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

    Read Also

    Role of AI in the Retail Sector

    Role of AI in the Retail Sector

    How Can Smart Retail Tech Help In A Post-Covid Retail Environment?

    How Can Smart Retail Tech Help In A Post-Covid Retail Environment?

    How Cognitive Computing Transforms Healthcare?

    How Cognitive Computing Transforms Healthcare?

    How to Establish Effective Cybersecurity Leadership in Post-COVID Era?

    How to Establish Effective Cybersecurity Leadership in Post-COVID Era?

    Disrupted Employees and Cybersecurity Risks

    Disrupted Employees and Cybersecurity Risks

    The Importance of Cognitive Analytics in Business Growth

    The Importance of Cognitive Analytics in Business Growth

    Loading...

    Copyright © 2021 APAC CIOoutlook. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Use and Privacy and Anti Spam Policy 

    |  Sitemap |  Subscribe

    follow on linkedinfollow on twitter follow on rss
    This content is copyright protected

    However, if you would like to share the information in this article, you may use the link below:

    https://www.apacciooutlook.com/news/preventing-opioid-use-disorder-with-resetotm-nwid-6250.html